FMP
AMEX
2.19 USD
0.07 (3.20%)
Mr. Motti Farbstein
Healthcare
Biotechnology
https://www.canfite.com
AMEX
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops ...
0001536196
US13471N3008
13471N201
10 Bareket Street
972 3 924 1114
IL
8
Nov 6, 2012
0001536196
AMEX
Biotechnology
Healthcare
13471N201
US13471N3008
IL
2.19
0.86
20.7k
10.93M
-
1.52-3.33
-0
-
-
-
-
-1.48
-
https://www.canfite.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.